Avantor (NYSE:AVTR – Get Rating) had its price target cut by research analysts at Morgan Stanley from $37.00 to $30.00 in a research note issued on Tuesday, Stock Target Advisor reports. The firm currently has an “overweight” rating on the stock. Morgan Stanley’s target price points to a potential upside of 50.45% from the stock’s current price.
Several other research firms have also issued reports on AVTR. Barclays decreased their target price on Avantor from $30.00 to $25.00 and set an “overweight” rating on the stock in a research note on Thursday, October 6th. UBS Group cut their price target on Avantor to $42.00 in a report on Thursday, September 15th. Robert W. Baird cut their price target on Avantor from $35.00 to $32.00 and set an “outperform” rating on the stock in a report on Thursday, October 6th. TheStreet downgraded Avantor from a “b-” rating to a “c+” rating in a report on Wednesday, September 21st. Finally, Cowen downgraded Avantor from an “outperform” rating to a “market perform” rating and cut their price target for the stock from $39.00 to $28.00 in a report on Wednesday, September 14th. Three analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $31.43.
Avantor Stock Performance
Shares of Avantor stock opened at $19.94 on Tuesday. Avantor has a 52 week low of $18.82 and a 52 week high of $42.48. The business’s fifty day simple moving average is $22.76 and its 200-day simple moving average is $27.88. The firm has a market cap of $13.44 billion, a PE ratio of 21.44 and a beta of 1.41. The company has a quick ratio of 1.05, a current ratio of 1.64 and a debt-to-equity ratio of 1.41.
Avantor (NYSE:AVTR – Get Rating) last posted its earnings results on Thursday, July 28th. The company reported $0.37 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.38 by ($0.01). Avantor had a return on equity of 27.14% and a net margin of 8.27%. The firm had revenue of $1.91 billion for the quarter, compared to analyst estimates of $1.98 billion. During the same period in the previous year, the company posted $0.35 EPS. Avantor’s revenue was up 2.7% on a year-over-year basis. Equities analysts forecast that Avantor will post 1.43 earnings per share for the current year.
Institutional Trading of Avantor
A number of hedge funds have recently added to or reduced their stakes in the stock. Xponance Inc. lifted its position in Avantor by 1.9% during the 3rd quarter. Xponance Inc. now owns 68,658 shares of the company’s stock worth $1,346,000 after acquiring an additional 1,289 shares during the period. Tandem Capital Management Corp ADV acquired a new stake in Avantor during the 3rd quarter worth approximately $986,000. TFC Financial Management acquired a new stake in Avantor during the 3rd quarter worth approximately $51,000. Whittier Trust Co. of Nevada Inc. lifted its holdings in shares of Avantor by 8.0% in the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 87,739 shares of the company’s stock valued at $1,719,000 after buying an additional 6,495 shares during the period. Finally, Whittier Trust Co. lifted its holdings in shares of Avantor by 4.3% in the 3rd quarter. Whittier Trust Co. now owns 163,095 shares of the company’s stock valued at $3,195,000 after buying an additional 6,769 shares during the period. 81.22% of the stock is owned by institutional investors and hedge funds.
About Avantor
Avantor, Inc provides products and services to customers in biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Avantor, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Avantor wasn’t on the list.
While Avantor currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
Source: news.google.com
